Inclusion Criteria-

          -  Confirmed diagnosis of multiple myeloma with measurable disease, as defined by the
             presence of M immunoglobulin protein in serum electrophoresis of at least 0.5 g/dL for
             IgG or 0.5 g/dL for IgA or urinary excretion of at least 200 mg monoclonal light chain
             per 24 hours.

          -  Clinical diagnosis of multiple myeloma requiring treatment that has relapsed after or
             proven refractory to at least three prior treatment regimens, and in the opinion of
             the investigator must not be candidates for any FDA approved drug known to provide
             clinical benefit.

          -  All acute toxicities from any prior therapy (radiotherapy, chemotherapy, or surgical
             procedures) resolved to Grade ≤ 2, NCI CTCAE.

          -  Serum potassium and magnesium levels within institutional normal limits. Total serum
             calcium or ionized calcium level must be greater than or equal to the lower limit of
             normal.

          -  Greater than 25% of myeloma plasmocytes from bone marrow must be CD33 positive.

          -  Required baseline laboratory data including: White blood cell count, Absolute
             neutrophil count (ANC), Platelets, Hemoglobin, Serum creatinine, AST, Creatinine
             clearance, Bilirubin , AST and ALT , FEV1/FVC

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

        Exclusion Criteria-

          -  Sex and Reproductive Status

               -  Women of child bearing potential (WOCBP) who are unwilling or unable to use an
                  acceptable method to avoid pregnancy for the entire study period and for at least
                  one month (4 weeks) before and for at least six months (6 months) after the last
                  dose of study medication.

               -  Women who are pregnant or breastfeeding

               -  Women with a positive pregnancy test on enrollment or prior to investigational
                  product administration.

               -  Men whose sexual partners are WOCBP, who are unwilling or unable to use an
                  acceptable method to avoid pregnancy for the entire study period and for at least
                  six months (6 months) after completion of study medication.

          -  Target Disease Exceptions

               -  Concurrent therapy with any other investigational agent.

               -  Concomitant therapy with bisphosphonates.

               -  Pathological fracture within 3 months prior to treatment;

               -  Symptomatic spinal cord compression; .

          -  Medical History and Concurrent Diseases

               -  Treatment with chemotherapy or biological therapy 3 weeks prior to enrollment;

               -  Presence of HAHA on screening

               -  No bone marrow transplant within 3 months prior to treatment initiation

               -  Prior treatment with radiation to cumulative maximum tolerated dose

               -  Clinically significant cardiac disease (NYHA Class III or IV) including
                  preexisting arrhythmia (such as ventricular tachycardia, ventricular
                  fibrillation, or "Torsade de Pointes")

               -  Myocardial infarction, uncontrolled angina within 6 months, congestive heart
                  failure, or cardiomyopathy.

               -  Abnormal QTc interval prolonged (> 450 msec) after electrolytes have been
                  corrected on baseline ECG.

               -  Clinically significant pleural effusion in the previous 12 months or current
                  ascites.

               -  Clinically-significant coagulation or platelet function disorder (eg, known von
                  Willebrand's disease).

               -  Prior or concurrent malignancy, except for the following:

                  i) Adequately treated basal cell or squamous cell skin cancer ii) Cervical
                  carcinoma in situ iii) Adequately treated Stage I or II cancer from which the
                  subject is currently in complete remission iv) Or any other cancer from which the
                  subject has been disease-free for 3 years.

          -  Physical and Laboratory Test Findings

             o Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality, serious uncontrolled medical disorder or active infection that may
             increase the risk associated with study participation or study drug administration or
             may interfere with the interpretation of study results and, in the judgment of the
             investigator, would make the subject inappropriate for this study.

          -  Allergies and Adverse Drug Reactions

             o Intolerance to humanized monoclonal antibodies

          -  Other Exclusion Criteria

               -  Prisoners or subjects who are involuntarily incarcerated.

               -  Subjects who are compulsorily detained for treatment of either a psychiatric or
                  physical (eg, infectious disease) illness.

          -  Treatment with radiation within 6 weeks

          -  Active serious infections uncontrolled by antibiotics

          -  Clinically significant pulmonary disease